secwatch.observer — SEC 8-K summary
======================================

Issuer:     Septerna, Inc. (SEPN)
CIK:        0001984086
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001193125-26-098489
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Septerna posts Q4 net loss $10.7M, highlights positive Phase 1 data for SEP-631
-------------------------------------------------------------------------------

- Phase 1 data: SEP-631 well-tolerated, once-daily oral dosing, complete wheal inhibition at 10 mg; Phase 2b in CSU planned H2 2026.
- SEP-479 PTH1R agonist on track for Phase 1 initiation in first half of 2026.
- Cash $548.7M at Dec 31, 2025; runway at least into 2029 (includes $195M upfront from Novo Nordisk).
- Q4 2025 revenue $24.1M (collaboration revenue); net loss $10.7M vs $20.7M loss in Q4 2024.
- Appointed Mark A. Wilson as chief legal officer in January 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1984086/000119312526098489/0001193125-26-098489-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1984086/000119312526098489/sepn-20260309.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-098489

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer